Palo Alto, California, United States The main office of represented VC is situated in the Palo Alto. The company was established in North America in United States.
The typical case for the fund is to invest in rounds with 4-5 participants. Despite the Prospect Venture Partners, startups are often financed by Venrock, Three Arch Partners, New Enterprise Associates. The meaningful sponsors for the fund in investment in the same round are Versant Ventures, Three Arch Partners, ARCH Venture Partners. In the next rounds fund is usually obtained by New Enterprise Associates, Alta Partners, Versant Ventures.
Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Kythera Biopharmaceuticals, NGM Biopharmaceuticals, Topica Pharmaceuticals. The fund has exact preference in a number of founders of portfolio startups. If startup sums 3 or 5+ of the founder, the chance for it to be financed is low. We can highlight the next thriving fund investment areas, such as Biopharma, Health Care. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States.
The fund is generally included in 2-6 deals every year. The high activity for fund was in 2004. Deals in the range of 10 - 50 millions dollars are the general things for fund. The real fund results show that this VC is 2 percentage points more often commits exit comparing to other companies. The top amount of exits for fund were in 2019. The average startup value when the investment from Prospect Venture Partners is 10-50 millions dollars. This Prospect Venture Partners works on 8 percentage points less the average amount of lead investments comparing to the other organizations.
This organization was formed by Alex Barkas. Besides them, we counted 1 critical employee of this fund in our database.
Related Funds
Funds with similar focus
| Fund Name | Location |
| ACG Qingbao She | - |
| Belden | Missouri, St Louis, United States |
| Competitive Technologies | Connecticut, Fairfield, United States |
| Creation Venture Partners | Chaoyang, China, Liaoning |
| Gaopeng Gong Chuang | China, Guangdong, Shenzhen |
| Harbor Street Ventures | Chicago, Illinois, United States |
| IHAG Holding | Switzerland, Zürich, Zurich |
| Impala Ventures | - |
| JSTV.com | China, Jiangsu, Nanjing |
| King Star Capital | - |
| KOSHIDAKA HOLDINGS | Chiba Prefecture, Japan, Tateyama |
| MMC Technology Ventures | - |
| Naftali Investments | - |
| Northern Right Capital | - |
| Scenic Investments | - |
| TAO Ventures (Australia) | - |
| Unshackled Ventures | California, Palo Alto, United States |
| Vento Security Holdings | Massachusetts, Nantucket, United States |
| Wix Capital | Israel, Tel Aviv, Tel Aviv District |
| Xinyu Yueyun | China, Jiangxi, Xinyu |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Nora Therapeutics | $18M | 17 Apr 2014 | Palo Alto, California, United States | ||
Element Science | $12M | 19 Mar 2014 | San Francisco, California, United States | ||
NinePoint Medical | $34M | 18 Mar 2014 | Cambridge, Massachusetts, United States | ||
NGM Biopharmaceuticals | $50M | 18 Jul 2013 | South San Francisco, California, United States | ||
SentreHEART | $26M | 04 Jun 2012 | Redwood City, California, United States | ||
Topica Pharmaceuticals | $27M | 18 Oct 2011 | Palo Alto, California, United States | ||
| $4M | 11 Oct 2011 | Pennsylvania, United States | |||
Satori Pharmaceuticals | $7M | 05 Jan 2011 | Cambridge, Massachusetts, United States | ||
NinePoint Medical | $33M | 14 Oct 2010 | Cambridge, Massachusetts, United States |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Nora Therapeutics | $18M | 17 Apr 2014 | Palo Alto, California, United States | ||
Element Science | $12M | 19 Mar 2014 | San Francisco, California, United States | ||
NinePoint Medical | $34M | 18 Mar 2014 | Cambridge, Massachusetts, United States | ||
NGM Biopharmaceuticals | $50M | 18 Jul 2013 | South San Francisco, California, United States | ||
SentreHEART | $26M | 04 Jun 2012 | Redwood City, California, United States | ||
Topica Pharmaceuticals | $27M | 18 Oct 2011 | Palo Alto, California, United States | ||
| $4M | 11 Oct 2011 | Pennsylvania, United States | |||
Satori Pharmaceuticals | $7M | 05 Jan 2011 | Cambridge, Massachusetts, United States | ||
NinePoint Medical | $33M | 14 Oct 2010 | Cambridge, Massachusetts, United States |
